Home / Market News / $BSEM

$BSEM news and market catalysts

The 9 most recent market catalysts affecting $BSEM, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

9 catalysts 2 high impact 2 bullish 3 bearish Biotechnology
Nov 13, 2026 Corporate Catalyst Bullish Impact 75
BioStem Technologies Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance
BioStem Technologies announced its Q3 2026 financial results, reporting $7.6 million in net revenue and a GAAP net loss of $11.4 million. The company raised its full-year 2026 reve…
Oct 1, 2026 Corporate Catalyst Neutral Impact 65
BioStem Secures US Patent, Additional US And Mexico Allowances For Tissue Technologies
BioStem Technologies announced the issuance of a new US patent and several notices of allowance for additional patent applications in both the US and Mexico. This development is si…
Sep 30, 2026 Corporate Catalyst Bearish Impact 75
BioStem Technologies shares are trading lower after the company announced a $3 million private placement of shares and warrants at $4.08 per share.
The private placement of shares and warrants at $4.08 per share is a significant corporate catalyst for BioStem Technologies. While it provides the company with $3 million in capit…
Sep 30, 2026 Corporate Catalyst Neutral Impact 55
BioStem Technologies Announces $3M Private Placement Of Shares And Warrants At $4.08/Share
This private placement provides BioStem Technologies with $3 million in capital, which can be used for R&D, operational expenses, or expansion. While the issuance of new shares and…
Sep 18, 2026 Corporate Catalyst Bullish Impact 85
BioStem Technologies shares are trading higher after the company announced it entered into a $40 million Committed Equity Facility with Roth Principal Investments.
This headline represents a significant corporate catalyst for BioStem Technologies. The $40 million committed equity facility provides a substantial capital injection, addressing p…
Sep 18, 2026 Corporate Catalyst Neutral Impact 75
BioStem Technologies Announces $40M Committed Equity Facility With Roth Principal Investments For Working Capital, General Corporate Purposes
The $40M committed equity facility provides BioStem Technologies (BSEM) with crucial working capital and funds for general corporate purposes, significantly de-risking its financia…
Aug 13, 2026 Corporate Catalyst Bearish Impact 75
BioStem Technologies shares are trading lower after the company reported a year-over-year decrease in Q2 sales results.
The headline indicates a direct corporate catalyst impacting BioStem Technologies (BSEM). A year-over-year decrease in Q2 sales is a strong negative signal to investors, suggesting…
Aug 12, 2026 Corporate Catalyst Bearish Impact 92
BioStem Technologies Q2 EPS $(0.52), Sales $7.899M Down From $10.963M YoY
BioStem Technologies (BSEM) announced its Q2 earnings, reporting a loss of $(0.52) per share and sales of $7.899 million. This represents a substantial 27.95% year-over-year decrea…
Aug 6, 2026 Corporate Catalyst Neutral Impact 65
BioStem Technologies Announces It Received Nasdaq Approval For The Company’s Common Stock For Listing On The Nasdaq Capital Market; Co. To Begin Trading On Nasdaq On August 7, 2026 Under The Ticker Symbol "BSEM"
BioStem Technologies announced that Nasdaq has approved its common stock for listing on The Nasdaq Capital Market. This is a positive development for the company as uplisting to a …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.